In vitro and in vivo experiments demonstrated that IL‐33 and BTZ synergistically exerted anti‐MM efficacy via stimulating excessive accumulation of ROS, thereby attenuating NF‐κB signal and suppressing stemness properties of MM cells. The gene discussed is NFKB1; the disease is Miyoshi myopathy.